Johnson & Johnson launched a new large-scale trial on Monday to test a two-dose regimen of its experimental COVID-19 vaccine. The late-stage study will evaluate if a second dose provides longer protection than a standard one-dose vaccine. Johnson & Johnson is launching a large-scale trial to test two doses of its experimental COVID-19 vaccine and enroll up to 30,000 participants. Pictured: The experimental vaccine being produced by Johnson & JohnsonThe vaccine uses genetic material from the coronavirus with the genes of the virus that causes the common cold to induce an immune response. The latest contract is priced at roughly $10 per vaccine dose, including a previous $456 million the government promised to J&J for vaccine development in March.

Source: Daily Mail November 16, 2020 14:28 UTC